Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI939 + sintilimab in advanced lung cancer
NCT04672356Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Jan 2021
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of tamgiblimab in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) (2 arms), sponsored by Innovent Biologics. Primary endpoints: Adverse Events at 3 months and Recommended Phase II Dose at 2 months. Started Jan 2021; status: completed.
02
Drugs
tamgiblimab
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04672356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04672356.